Characterization of the uptake of 16α-([18F]fluoro)-17β-estradiol in DMBA-induced mammary tumors

https://doi.org/10.1016/0883-2897(87)90156-5Get rights and content

Abstract

In order to investigate possible correlations between the uptake of 16α-([18F]fluoro)-17β-estradiol (18F-ES) by 7,12-dimethylbenz(a) anthracene (DMBA)-induced tumors in rats and the estrogen receptor (ER) content of these tumors, a comprehensive study was performed in which the tissue distribution of 18F-ES was measured in tumor-bearing rats, together with simultaneous measurements of blood volume (by technetium-labeled red blood cells) and blood flow (by iodoantipyrine infusion). In addition, the time course of 18F-ES metabolism and the tissue distribution of the metabolites was studied. Metabolism of 18F-ES is very rapid, and after 2 h, most of the activity in blood and nontarget tissues is due to metabolites; target tissue activity, however, is due mainly to unmetabolized compound. Most of the circulating activity, both 18F-ES and its metabolites, is strongly associated with macromolecules or cells, and while the metabolites are not taken up selectively by target tissues, they do enter nontarget tissues. Tumor blood volume and blood flow vary widely, but not in a way that appears related to tumor necrosis. The uptake of 18F-ES by the uterus and DMBA-induced mammary tumors of adult rats reaches maximum levels (ca 0.35 and 0.10% I.D./g·kg, respectively) at early times (0–1 h), and drops slowly thereafter. The uterus to nontarget or tumour to nontarget tissue ratios, however, start low and continue to increase, reaching maximum levels (ca 20 and 15, respectively) at 2–3 h. There does not, however, appear to be a simple relationship between tumor uptake (either as % I.D./g·kg or tumor to nontarget ratio) measured at a single 3 h time point and tumor ER content, even considering differences in tumor blood flow. This suggests that an estimation of tumor ER content will require the application of more complex pharmacodynamic models that involve the measurement of the complete profile of receptor lignad uptake, retention, and washout from target to nontarget areas. The application of such models will be assisted by the development of estrogen receptor binding ligands that are not converted to circulating metabolites.

References (41)

  • M.J. Welch et al.

    Comparison in animal models of 18F-spiroperidol and 18 F-haloperidol: potential agents for imaging the dopamine receptor

    Life Sci.

    (1983)
  • W.C. Eckelman et al.

    External imaging of cerebral muscarinic acetylcholine receptors

    Science

    (1984)
  • A. Feenstra et al.

    Estrogen receptor binding radiopharmaceuticals: II. Tissue distribution 17α-methylestradiol in normal and tumor-bearing rats

    J. Nucl. Med.

    (1983)
  • J.S. Fowler et al.

    [11C]Spiroperidol: Synthesis, specific activity determination and biodistribution in mice

    J. Nucl. Med.

    (1982)
  • J.J. Frost et al.

    In vivo studies of opiate receptors

    Ann. Neurol.

    (1984)
  • R.N. Hanson et al.

    Preparation and evaluation of 17α-[125I]iodovinyl-llβ-methoxy-estradiol as a highly selective radioligand for tissues containing estrogen receptors: concise communication

    J. Nucl. Med.

    (1980)
  • R.N. Hanson et al.

    Preparation and evaluation of 17α-[125I]Iodovinyl-llβ-methoxyestrodiol as a highly selective radioligand for tissues containing estrogen receptors: Concise Communication

    J. Nucl. Med.

    (1984)
  • D.F. Heiman et al.

    Estrogen receptor based imaging agents 1: Synthesis and receptor binding affinity of some aromatic and D-ring halogenated esterogens

    J. Med. Chem.

    (1980)
  • E. Hirai et al.

    First pass metabolism of ethinyl estradiol in dogs and rats

    J. Pharmaceut. Sci.

    (1981)
  • R.B. Hochberg

    Iodine-125-labeled estradiol, a gamma-emitting analog of estradiol that binds to the estrogen receptor

    Science

    (1979)
  • Cited by (58)

    • The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[<sup>18</sup>F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review

      2021, Nuclear Medicine and Biology
      Citation Excerpt :

      Following our first report in 1984 of the favorable biodistribution characteristics of FES in immature female rats [10], we imaged a series of DMBA-induced mammary tumors in adult female rats. We examined as a function of time, metabolism and tumor uptake of FES, as well as blood volume and blood flow in tumors and possible correlations between uptake and ER levels in tumors and in the uterus, finding that the relationships among these factors were complex [73]. We also performed a dose-response study of FES in immature female rats [74]; increasing doses of FES were obtained by adding progressively larger quantities of unlabeled FES.

    • Development of Companion Diagnostics

      2016, Seminars in Nuclear Medicine
      Citation Excerpt :

      The binding characteristics of this positron-emitting radiopharmaceutical are similar to estradiol for both the ER and SHBG,59 making it an excellent marker of ER expression. Like estradiol, most of FES within the blood is bound to protein, primarily SHBG and albumin, and the exact ratio depends on the concentration of SHBG.60-62 As with any other steroid, FES is metabolized by the liver.60

    • 16α-[<sup>18</sup>F]-fluoro-17ß-oestradiol ([<sup>18</sup>F]FES): A biomarker for imaging oestrogen receptor expression with positron emission tomography (PET)

      2015, Medecine Nucleaire
      Citation Excerpt :

      Analogues of oestradiol must display a good affinity for SHBG and albumin. In rats and in humans, about 95% of [18F]FES are bound to plasma proteins (either SBG or albumin) [20,21]. Even though most of [18F]FES initially binds to albumin right after intravenous administration, very quickly thereafter the tracer is transferred to SBG [22].

    • Comparative pharmacokinetics and tissue distribution analysis of systemically administered 17-β-estradiol and its metabolites in vivo delivered using a cationic nanoemulsion or a peptide-modified nanoemulsion system for targeting atherosclerosis

      2014, Journal of Controlled Release
      Citation Excerpt :

      Thus, within an hour of intravenous administration of 17-βE using the solution, and the DOTAP nanoemulsion system, the circulating levels of the parent compound as well as the metabolites decreased to less than 5% of the injected dose. Similar PK parameters and distribution profile of 17-βE solution have been observed in humans and rats with slight species based differences on systemic administration of 17-βE solution [29–31]. However, in our study, at all time points, the circulating levels of both the parent compound and metabolites ESS and EST in plasma were significantly greater when administered using the CREKA-peptide modified nanoemulsion system relative to the solution as well as the DOTAP nanoemulsion system.

    • PET imaging of oestrogen receptors in patients with breast cancer

      2013, The Lancet Oncology
      Citation Excerpt :

      After the initial rapid decline, the activity of unconjugated 18F-FES blood declines slowly, over around 50 min, and by 60 min reaches less than 5% of peak value. The presence of conjugated 18F-FES metabolites is unlikely to affect tumour 18F-FES uptake because they cannot bind oestrogen receptors and their polarity prevents penetration of cell membranes.23,59 Unconjugated 18F-FES is bound to carrier proteins SHBG (45%) and albumin (45%) in serum, and the remainder circulates in free form.56

    View all citing articles on Scopus

    This work was supported by DOE Grant DE-FG02-84ER60218 and NIH Grants HL13851 and CA25836.

    View full text